Clinical Trials

Status
Published

Recently Activated

SHOW MORE

Active Filters

    Open
    Phase
    II
    Accrual
    0%
    SWOG Clinical Trial Number
    S2007

    A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

    Status Notes
    Activation - Effective 12/15/20, 12:00 PM Pacific Time

    All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
    Research Committee(s)
    Breast Cancer
    Activated
    12-15-2020
    ClinicalTrials.gov Registry Number
    04647916
    Open
    Accrual
    0%
    SWOG Clinical Trial Number
    S1925

    A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

    Status Notes
    Active effective 12/14/20
    Research Committee(s)
    Leukemia
    Symptom Control and Quality of Life
    Activated
    12-14-2020
    ClinicalTrials.gov Registry Number
    04269902
    Open
    Phase
    II
    Accrual
    0%
    SWOG Clinical Trial Number
    S2001

    Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects

    Status Notes
    Activation, Effective 12/04/2020, 3:00 pm eastern
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-04-2020
    ClinicalTrials.gov Registry Number
    NCT04548752
    Open
    Phase
    II
    Accrual
    1%
    SWOG Clinical Trial Number
    S2000

    A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

    Status Notes
    Activation, Effective 9/23/2020, 2:00 pm eastern
    Research Committee(s)
    Melanoma
    Activated
    09-23-2020
    ClinicalTrials.gov Registry Number
    NCT04511013
    Open
    Phase
    I-II
    Accrual
    0%
    SWOG Clinical Trial Number
    S1905

    A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

    Status Notes
    This study is open to accrual effective August 17, 2020 at 12:00 p.m. Pacific.
    Research Committee(s)
    Leukemia
    Lymphoma
    Activated
    08-17-2020
    ClinicalTrials.gov Registry Number
    NCT#04315324